Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | Applied Digital | Applied Optoelectronics | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | none The FY2026 10-K (filed 2026-07-29) shows contracted revenue, not a demonstrated competitive edge. About 1,410 MW is leased under 15-year take-or-pay, non-cancellable base terms worth about $36.2 billion, but only about 100 MW of the roughly 1.5 GW that is contracted and either operating or under construction was operating and earning revenue at May 31, 2026, and Item 1A says "lessees may have the right to terminate applicable leases if there are significant delays in construction." Item 1A also concedes "We do not have the resources to compete with larger providers of similar products or services at this time," and the Competition section names 13 power-advantaged developers the company competes with. Signed leases give revenue visibility, but the filing does not show a durable advantage. | narrow FY2025 10-K (Item 1, 'Our Technology' and 'Competition'): AOI is vertically integrated down to its own laser chips, fabricated exclusively in Sugar Land, TX with a combined MBE+MOCVD process it believes is 'unique in our industry' and 'difficult and time-consuming for other vendors to replicate'; the same filing calls the optical networking market 'intensely competitive' with larger, better-resourced rivals (Coherent, InnoLight, Eoptolink, Lumentum et al.), so the process edge is real but not dominant — https://www.sec.gov/Archives/edgar/data/1158114/000143774926005875/aaoi20251231_10k.htm |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | none The 10-K claims three advantages: power-advantaged sites (it believes securing power and interconnection ahead of demand is 'the principal constraint on new HPC capacity and a core differentiator for us from many of our competitors'), a standardized 'franchise-style' design, and hyperscaler master service and master telecom service agreements 'that are difficult to obtain.' The filing does not show any of them to be durable. Its Competition section says competition 'centers on securing and developing sites with access to large-scale, reliable, and cost-competitive power and interconnection' and names 13 power-advantaged developers going after the same leases, and Item 1A concedes it lacks the resources to compete with larger providers. Signed leases are take-or-pay and non-cancellable, so a tenant leaving for convenience owes 'the full remaining contractual value,' but that is contractual lock-in on each lease rather than a moat source, so no moat type is assigned. | intangibles ip FY2025 10-K (Item 1, 'Our Technology' / 'Intellectual Property'): the differentiation the company itself leads with is process know-how — proprietary MBE laser fabrication combined with MOCVD ('to our knowledge, we are unique in incorporating MBE processes in the production of communications lasers in high volume'), 199 issued U.S. patents plus 140 in China/Taiwan, and explicit reliance on unpatented trade secrets — https://www.sec.gov/Archives/edgar/data/1158114/000143774926005875/aaoi20251231_10k.htm |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | behind The 10-K makes no leadership claim and gives no ranking or share figure. Item 1A concedes "We do not have the resources to compete with larger providers of similar products or services at this time" and that some rivals have "substantially greater liquidity and financial resources than we do." Its Competition section places APLD against established operators (Digital Realty, Equinix), hyperscalers that build their own capacity, independent developers and 13 named power-advantaged developers (IREN, Cipher Digital, TeraWulf, Hut 8, Riot, CleanSpark, HIVE, Core Scientific, Bitdeer, Galaxy Digital, Fermi, Keel Infrastructure, MARA). | fast follower Bifurcated: the FY2025 10-K self-describes an 'industry-leading position in the CATV market' serving 'a majority of the largest CATV equipment manufacturers,' but in datacenter optics — its AI-relevant line — AAOI is not among the vendors LightCounting's March 2026 quarterly update credits with record 2025 results (InnoLight, Coherent, Eoptolink, Fabrinet, Lumentum), so company-level it reads as a fast follower chasing the 800G/1.6T leaders — https://www.lightcounting.com/newsletter/en/march-2026-quarterly-market-update-380 |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | weak Item 1A says "Due to the limited number of hyperscalers, we expect that a limited number of customers will continue to account for a high percentage of our revenue for the foreseeable future," and that if customers' equipment usage declines or they discontinue use of its facilities, APLD "may be compelled to lower our lease prices in some instances or risk losing a significant customer." One customer was 59% of FY2026 revenue from continuing operations. Take-or-pay, non-cancellable terms protect contracted revenue over the base term, and Note 19 reports a $39.1M HPC Hosting segment profit on $385.3M of segment revenue in FY2026, but those terms are agreed with a small group of concentrated buyers. | moderate FY2025 10-K (MD&A cost/pricing discussion): gross margin fluctuates with 'decreases in average selling prices,' but in CATV — 53.8% of 2025 revenue — the company states 'we believe we face less downward price pressure than many of our competitors' due to the value of its outsourced design services; FY2025 gross margin was 30.0%, up from 24.8% in 2024 — https://www.sec.gov/Archives/edgar/data/1158114/000143774926005875/aaoi20251231_10k.htm |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | Applied Digital designs, builds and operates purpose-built, liquid-cooled HPC data centers, which it calls 'AI factories', and leases the capacity to CoreWeave and investment-grade hyperscalers. At May 31, 2026 its 10-K lists five campuses (Polaris Forge 1-3 and Delta Forge 1-2) with about 1,410 MW contracted under roughly 15-year take-or-pay, non-cancellable leases worth about $36.2 billion over the base terms. The filing claims three sources of advantage: it controls power-advantaged sites, it uses a standardized 'franchise-style' design built to deliver about 150 MW in about 14 to 18 months, and it holds hyperscaler master agreements that are 'difficult to obtain.' The same document shows how early the company is. About 100 MW was operating and earning revenue. One customer was 59% of FY2026 revenue from continuing operations. It competes with Digital Realty, Equinix, hyperscalers that build their own capacity and 13 named power-advantaged developers, and it concedes that it lacks the resources to compete with larger providers. Signed leases give long-dated revenue visibility, but the filing does not show a durable competitive advantage. | AOI is a vertically integrated fiber-optics maker whose FY2025 revenue of $455.7M split 53.8% CATV and 42.9% internet datacenter (FY2025 10-K). Its defensible core is laser-fab process IP (MBE+MOCVD, all chips made in Sugar Land) plus highly automated U.S. module production the 10-K pitches as a supply-chain-security advantage. The AI datacenter line is ramping hard — Q2 2026 was a fifth consecutive record revenue quarter at $191.9M with 800G shipments more than doubling sequentially and demand forecast to outpace capacity through mid-2027 (Q2 2026 release) — but AAOI is absent from LightCounting's list of vendors that set records in the $23.8B 2025 transceiver market (InnoLight, Coherent, Eoptolink), so it ramps as a challenger, not a leader. The moat is narrow and concentration-risked: Digicomm was 53.1% and Microsoft 28.8% of 2025 revenue (10-K). |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | Developer and landlord of power-advantaged, liquid-cooled AI data-center capacity, leased long-term to CoreWeave and investment-grade hyperscalers. | Upstream optics supplier to the AI buildout: sells 800G/1.6T transceivers into hyperscale datacenters (Microsoft was 28.8% of 2025 revenue; Oracle 12.4% in 2024) and lasers/turn-key HFC equipment into CATV via distributor Digicomm (53.1% of 2025 revenue), per the FY2025 10-K — https://www.sec.gov/Archives/edgar/data/1158114/000143774926005875/aaoi20251231_10k.htm |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.20 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. |